Aim: Human urotensin-II (UII) is a cyclic neuropeptide with potent vasoconstrictive activity in
the vasculature. The expression of UII and its receptor (UT) mRNA is detected at high levels …

Background: Circulating blood levels of human urotensin II (U-II), the most potent
vasoconstrictor peptide identified to date, are increased in patients with essential …

Human urotensin II (U-II), the most potent vasoconstrictor undecapeptide identified to date,
and its receptor (UT) are involved in the pathogenesis of systemic and pulmonary …

Urotensin II, through its interaction with its UT receptor, is a potent vasoactive peptide in
humans and in several animal models. Recent studies have demonstrated elevated plasma …

Aims/hypothesis The small, highly conserved vasoactive peptide urotensin II (UII) is
upregulated in atherosclerosis. However, its effects in diabetes-associated atherosclerosis …

Urotensin II (UII) is a vasoactive peptide composed of 11 amino acids that has been
implicated to contribute to the development of cardiovascular disease. The purpose of this …

Human U-II (urotensin-II), the most potent vasoconstrictor peptide identified to date, is
associated with cardiovascular disease. A single nucleotide polymorphism (S89N) in the …

Urotensin-II (U-II), a cyclic undecapeptide, and its receptor, UT, have been linked to vascular
and cardiac remodeling. In patients with coronary artery disease (CAD), it has been shown …

Hypertension is a well-known risk factor for atherosclerosis, but the molecular mechanisms
that link elevated blood pressure to the progression of atherosclerosis remain unclear …

Accumulated evidence shows that elevated urotensin II (UII) levels are associated with
cardiovascular diseases. However, the role of UII in the initiation, progression, and …